Author

S. Muro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Mukalel· 1 shared A. Rodriguez-Garcia· 1 shared B. Ruan· 1 shared C. F. Greineder· 1 shared C. H. Villa· 1 shared D. A. Rozak· 1 shared D. J. Weber· 1 shared D. T. Gallagher· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Mukalel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeted nanocarriers coopting pulmonary leukocytes for drug delivery to the injured brain

P. M. Glassman, J. Nong, J. W. Myerson, V. Zuluaga-Ramirez, A. Rodriguez-Garcia, A. Mukalel, S. Omo-Lamai, L. R. Walsh, R. Y. Kiseleva, C. H. Villa, C. F. Greineder, S. E. Kasner, D. Weissman, M. J. Mitchell, S. Muro, , O. A. Marcos-Contreras

This paper demonstrates a strategy for targeted drug delivery to the injured brain by loading drugs onto pulmonary leukocytes using ICAM-targeting nanocarriers, showing increased brain uptake and therapeutic effect in a mouse model.

bioRxiv · Feb 4, 2022 · PreprintPharmacology & Toxicology

Engineering protein-specific proteases: targeting active RAS

Y. Chen, E. A. Toth, B. Ruan, E. J. Choi, R. Simmerman, Y. Chen, Y. He, R. Wang, R. Godoy-Ruiz, H. King, G. Custer, D. T. Gallagher, D. A. Rozak, M. Soloman, S. Muro, , P. N. Bryan

This study designs engineered proteases that specifically degrade active RAS by cleaving a conserved sequence in switch 2, showing efficacy in vitro and in human cell culture.

bioRxiv · Sep 21, 2020Biochemistry